{"id":48178,"date":"2022-09-09T17:02:11","date_gmt":"2022-09-09T15:02:11","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/verily-announces-1-billion-investment-round-to-fund-continued-growth-and-shares-changes-to-leadership-team\/"},"modified":"2022-09-09T17:02:11","modified_gmt":"2022-09-09T15:02:11","slug":"verily-announces-1-billion-investment-round-to-fund-continued-growth-and-shares-changes-to-leadership-team","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/verily-announces-1-billion-investment-round-to-fund-continued-growth-and-shares-changes-to-leadership-team\/","title":{"rendered":"Verily Announces $1 Billion Investment Round to Fund Continued Growth and Shares Changes to Leadership Team"},"content":{"rendered":"<div>\n<p class=\"bwalignc\">\nFounder and CEO Andy Conrad will become Executive Chairman<br \/>\n<br \/>President Stephen Gillett promoted to Chief Executive Officer\n<\/p>\n<p>SOUTH SAN FRANCISCO, Calif.&#8211;(BUSINESS WIRE)&#8211;Verily today announced a $1 billion dollar investment round led by Alphabet, that will be used to support the expansion of Verily\u2019s businesses focused on precision health. Verily is also announcing new roles for the company\u2019s top leadership.\n<\/p>\n<p><a href=\"https:\/\/mms.businesswire.com\/media\/20220909005363\/en\/1567001\/5\/Ver_Wordmark_RGB.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20220909005363\/en\/1567001\/21\/Ver_Wordmark_RGB.jpg\"><\/a><\/p>\n<p>\nThe new capital will be used to support a variety of the company\u2019s core initiatives focused on real world evidence generation, healthcare data platforms, research and care, and the underlying technology that drives this work, which all share the goal of making health care better and more tailored to individuals. The company will also consider further investment in strategic partnerships, global business development and potential acquisitions.\n<\/p>\n<p>\nAs the company enters its next phase of growth, company founder Andy Conrad will become Executive Chairman of the Verily Board and current president Stephen Gillett will be promoted to Chief Executive Officer, with both changes effective January 2023. These new roles are the result of thoughtful succession planning led by Conrad and the board and in recognition of the skills and experience required to lead Verily as it becomes a more operationally and commercially focused company executing on its precision health strategy.\n<\/p>\n<p>\nGillett joined Verily<b> <\/b>from Google<b> <\/b>in 2020 as an operational advisor to the company and to lead Verily\u2019s effort to establish a Cybersecurity Center of Excellence. In November of that year he was named Chief Operating Officer. Before joining Verily, Gillett was co-founder and CEO of Chronicle, an Alphabet cybersecurity company that is now part of Google Cloud. He continues to be an active advisor to GV and X. Prior to Alphabet, Gillett held a number of executive roles at companies in a variety of industry sectors including Best Buy, Starbucks and Symantec.\n<\/p>\n<p>\nSeparately, Deepak Ahuja, CFO, has decided to leave Verily for another opportunity. He will remain an advisor to Verily but depart his current role at the end of September. Verily will begin a search for his replacement immediately.\n<\/p>\n<p>\n<b>About Verily<\/b>\n<\/p>\n<p>\nVerily is a subsidiary of Alphabet that is using a data-driven, people-first approach to change the way people manage their health and the way healthcare is delivered. Launched from X in 2015, Verily\u2019s purpose is to bring the promise of precision health to everyone, every day. Verily is focused on generating and activating data from a wide variety of sources, including clinical, social, behavioral and the real world, to arrive at the best solutions for a person based on a comprehensive view of the evidence. Verily uses its recognized expertise and capabilities in technology, data science and healthcare to enable the entire healthcare ecosystem to drive better health outcomes. For more information, please visit verily.com.\n<\/p>\n<p> <b>Contacts<\/b> <\/p>\n<p>\n<b>Media<\/b>:<br \/>\n<br \/>Steven Cooper<br \/>\n<br \/>Head of Media Relations<br \/>\n<br \/><a target=\"_blank\" href=\"&#109;a&#x69;l&#x74;&#111;&#x3a;&#115;&#x6a;&#99;o&#x6f;p&#x40;&#118;&#x65;&#114;&#x69;&#108;&#x79;&#46;c&#x6f;m\" rel=\"nofollow noopener\" shape=\"rect\">&#x73;&#106;c&#x6f;&#111;p&#x40;&#118;e&#x72;&#105;l&#x79;&#46;c&#x6f;&#109;<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Founder and CEO Andy Conrad will become Executive Chairman President Stephen Gillett promoted to Chief Executive Officer SOUTH SAN FRANCISCO, Calif.&#8211;(BUSINESS WIRE)&#8211;Verily today announced a $1 billion dollar investment round led by Alphabet, that will be used to support the expansion of Verily\u2019s businesses focused on precision health. Verily is also announcing new roles for &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/verily-announces-1-billion-investment-round-to-fund-continued-growth-and-shares-changes-to-leadership-team\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-48178","6":"format-standard","7":"category-industry"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Verily Announces $1 Billion Investment Round to Fund Continued Growth and Shares Changes to Leadership Team - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/verily-announces-1-billion-investment-round-to-fund-continued-growth-and-shares-changes-to-leadership-team\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Verily Announces $1 Billion Investment Round to Fund Continued Growth and Shares Changes to Leadership Team - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"Founder and CEO Andy Conrad will become Executive Chairman President Stephen Gillett promoted to Chief Executive Officer SOUTH SAN FRANCISCO, Calif.&#8211;(BUSINESS WIRE)&#8211;Verily today announced a $1 billion dollar investment round led by Alphabet, that will be used to support the expansion of Verily\u2019s businesses focused on precision health. Verily is also announcing new roles for ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/verily-announces-1-billion-investment-round-to-fund-continued-growth-and-shares-changes-to-leadership-team\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-09-09T15:02:11+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220909005363\/en\/1567001\/21\/Ver_Wordmark_RGB.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/verily-announces-1-billion-investment-round-to-fund-continued-growth-and-shares-changes-to-leadership-team\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/verily-announces-1-billion-investment-round-to-fund-continued-growth-and-shares-changes-to-leadership-team\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Verily Announces $1 Billion Investment Round to Fund Continued Growth and Shares Changes to Leadership Team\",\"datePublished\":\"2022-09-09T15:02:11+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/verily-announces-1-billion-investment-round-to-fund-continued-growth-and-shares-changes-to-leadership-team\\\/\"},\"wordCount\":487,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/verily-announces-1-billion-investment-round-to-fund-continued-growth-and-shares-changes-to-leadership-team\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220909005363\\\/en\\\/1567001\\\/21\\\/Ver_Wordmark_RGB.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/verily-announces-1-billion-investment-round-to-fund-continued-growth-and-shares-changes-to-leadership-team\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/verily-announces-1-billion-investment-round-to-fund-continued-growth-and-shares-changes-to-leadership-team\\\/\",\"name\":\"Verily Announces $1 Billion Investment Round to Fund Continued Growth and Shares Changes to Leadership Team - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/verily-announces-1-billion-investment-round-to-fund-continued-growth-and-shares-changes-to-leadership-team\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/verily-announces-1-billion-investment-round-to-fund-continued-growth-and-shares-changes-to-leadership-team\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220909005363\\\/en\\\/1567001\\\/21\\\/Ver_Wordmark_RGB.jpg\",\"datePublished\":\"2022-09-09T15:02:11+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/verily-announces-1-billion-investment-round-to-fund-continued-growth-and-shares-changes-to-leadership-team\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/verily-announces-1-billion-investment-round-to-fund-continued-growth-and-shares-changes-to-leadership-team\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/verily-announces-1-billion-investment-round-to-fund-continued-growth-and-shares-changes-to-leadership-team\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220909005363\\\/en\\\/1567001\\\/21\\\/Ver_Wordmark_RGB.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220909005363\\\/en\\\/1567001\\\/21\\\/Ver_Wordmark_RGB.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/verily-announces-1-billion-investment-round-to-fund-continued-growth-and-shares-changes-to-leadership-team\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Verily Announces $1 Billion Investment Round to Fund Continued Growth and Shares Changes to Leadership Team\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Verily Announces $1 Billion Investment Round to Fund Continued Growth and Shares Changes to Leadership Team - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/verily-announces-1-billion-investment-round-to-fund-continued-growth-and-shares-changes-to-leadership-team\/","og_locale":"en_US","og_type":"article","og_title":"Verily Announces $1 Billion Investment Round to Fund Continued Growth and Shares Changes to Leadership Team - Pharma Trend","og_description":"Founder and CEO Andy Conrad will become Executive Chairman President Stephen Gillett promoted to Chief Executive Officer SOUTH SAN FRANCISCO, Calif.&#8211;(BUSINESS WIRE)&#8211;Verily today announced a $1 billion dollar investment round led by Alphabet, that will be used to support the expansion of Verily\u2019s businesses focused on precision health. Verily is also announcing new roles for ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/verily-announces-1-billion-investment-round-to-fund-continued-growth-and-shares-changes-to-leadership-team\/","og_site_name":"Pharma Trend","article_published_time":"2022-09-09T15:02:11+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220909005363\/en\/1567001\/21\/Ver_Wordmark_RGB.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/verily-announces-1-billion-investment-round-to-fund-continued-growth-and-shares-changes-to-leadership-team\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/verily-announces-1-billion-investment-round-to-fund-continued-growth-and-shares-changes-to-leadership-team\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Verily Announces $1 Billion Investment Round to Fund Continued Growth and Shares Changes to Leadership Team","datePublished":"2022-09-09T15:02:11+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/verily-announces-1-billion-investment-round-to-fund-continued-growth-and-shares-changes-to-leadership-team\/"},"wordCount":487,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/verily-announces-1-billion-investment-round-to-fund-continued-growth-and-shares-changes-to-leadership-team\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220909005363\/en\/1567001\/21\/Ver_Wordmark_RGB.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/verily-announces-1-billion-investment-round-to-fund-continued-growth-and-shares-changes-to-leadership-team\/","url":"https:\/\/pharma-trend.com\/en\/verily-announces-1-billion-investment-round-to-fund-continued-growth-and-shares-changes-to-leadership-team\/","name":"Verily Announces $1 Billion Investment Round to Fund Continued Growth and Shares Changes to Leadership Team - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/verily-announces-1-billion-investment-round-to-fund-continued-growth-and-shares-changes-to-leadership-team\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/verily-announces-1-billion-investment-round-to-fund-continued-growth-and-shares-changes-to-leadership-team\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220909005363\/en\/1567001\/21\/Ver_Wordmark_RGB.jpg","datePublished":"2022-09-09T15:02:11+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/verily-announces-1-billion-investment-round-to-fund-continued-growth-and-shares-changes-to-leadership-team\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/verily-announces-1-billion-investment-round-to-fund-continued-growth-and-shares-changes-to-leadership-team\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/verily-announces-1-billion-investment-round-to-fund-continued-growth-and-shares-changes-to-leadership-team\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220909005363\/en\/1567001\/21\/Ver_Wordmark_RGB.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220909005363\/en\/1567001\/21\/Ver_Wordmark_RGB.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/verily-announces-1-billion-investment-round-to-fund-continued-growth-and-shares-changes-to-leadership-team\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Verily Announces $1 Billion Investment Round to Fund Continued Growth and Shares Changes to Leadership Team"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/48178","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=48178"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/48178\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=48178"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=48178"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=48178"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}